661 related articles for article (PubMed ID: 16358233)
1. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
2. [CA-P control in haemodialysis and K/DOQI guidelines].
Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
[TBL] [Abstract][Full Text] [Related]
3. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
[TBL] [Abstract][Full Text] [Related]
5. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
Mahdavi-Mazdeh M; Zamyadi M; Norouzi S; Heidary Rouchi A
Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440
[TBL] [Abstract][Full Text] [Related]
6. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
7. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
8. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
9. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
Wazny LD; Raymond CB; Lesperance EM; Bernstein KN
CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
[TBL] [Abstract][Full Text] [Related]
10. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
11. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
12. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
13. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Kimata N; Akiba T; Pisoni RL; Albert JM; Satayathum S; Cruz JM; Akizawa T; Andreucci VE; Young EW; Port FK
Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
[TBL] [Abstract][Full Text] [Related]
14. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
15. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
16. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
17. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
18. The influences of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan.
Yokoyama K; Katoh N; Kasai K; Kubo H; Murai S; Shoji R; Imamura N; Saika S; Yumita S; Ishida M; Takasu S; Kono T; Yoshida Y; Wakabayashi T; Kimua Y; Hosoya T
Ther Apher Dial; 2006 Jun; 10(3):257-61. PubMed ID: 16817790
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
[TBL] [Abstract][Full Text] [Related]
20. Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic hemodialysis patients.
Molina Vila P; Sánchez Pérez P; Garrigós Almerich E; Peris Domingo A
Hemodial Int; 2008 Jan; 12(1):73-9. PubMed ID: 18271845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
